Valuation: Edesa Biotech, Inc.

Market Cap 3.74Cr 3.34Cr 3.09Cr 2.8Cr 5.23Cr 355.29Cr 5.32Cr 37Cr 15Cr 186.15Cr 14Cr 14Cr 586.88Cr P/E 2026 *
-1.39x
P/E 2027 * -1.34x
Enterprise Value 3.74Cr 3.34Cr 3.09Cr 2.8Cr 5.23Cr 355.29Cr 5.32Cr 37Cr 15Cr 186.15Cr 14Cr 14Cr 586.88Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.36%
1 week+7.78%
Current month-34.20%
1 month-30.23%
3 months-51.06%
6 months-59.14%
Current year+95.07%
1 week 2.57
Extreme 2.57
3.02
1 month 2.52
Extreme 2.52
4.27
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
62.65
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Free

Founder

6,893 0.0510%
01/09/26 Free

Founder

5,714 0.0593%
03/08/26 Free

Founder

5,324 0.0553%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+7.78%+2.97%-17.07% 3.73Cr
+2.41%+0.29%+42.02%+71.57% 6.33TCr
-0.15%+7.50%+11.01%+73.48% 5.49TCr
+0.57%+4.60%+10.07%+92.86% 5.33TCr
+0.37%+4.67%+27.03%+52.07% 4.58TCr
-1.21%+2.32%+21.80%+123.81% 4.35TCr
-0.37%+5.07%+249.91%+918.74% 4.02TCr
+0.05%+0.21%+18.26%+58.53% 3.35TCr
+1.19%-4.98%+29.01%-0.65% 2.37TCr
-0.38%+5.68%+36.43%+27.54% 2.38TCr
Average +0.28%+1.98%+44.85%+140.09% 3.82TCr
Weighted average by Cap. +0.38%+2.27%+47.67%+159.28%

Financials

2026 *2027 *
Net sales - -
Net income -1.75Cr -1.56Cr -1.45Cr -1.31Cr -2.45Cr -166.36Cr -2.49Cr -17Cr -6.89Cr -87Cr -6.58Cr -6.44Cr -274.79Cr -2.39Cr -2.13Cr -1.97Cr -1.79Cr -3.34Cr -226.67Cr -3.39Cr -24Cr -9.38Cr -118.76Cr -8.96Cr -8.77Cr -374.42Cr
Net Debt - -
Projected Income Statement - Annual - Edesa Biotech, Inc.
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
23/26/23 $2.770 +0.36% 18,476
22/26/22 $2.760 -3.16% 22,690
21/26/21 $2.850 +1.06% 39,305
20/26/20 $2.820 +1.44% 35,515
19/26/19 $2.780 +8.17% 25,039
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Edesa Biotech, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.770USD
Average target price
16.33USD
Spread / Average Target
+489.65%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Edesa Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. EDSA Stock